openfda-mcp-server
Related Servers
Alternatives to openfda-mcp-server
No user-submitted related servers found.
Related Servers
- FlicenseNot gradedqualityDmaintenanceEnables querying FDA drug approvals, device clearances (510(k)), recalls, and adverse events via the openFDA API, providing tools for clinical and pharmaceutical research.1-
- FlicenseNot gradedqualityDmaintenanceEnables AI agents to query and analyze FDA adverse events, drug labels, medical device clearances, and other public health datasets through natural language commands.14-
- AlicenseBqualityCmaintenanceEnables querying FDA drug label information including adverse reactions, warnings, and indications through natural language.510 npmGPL 3.0
- AlicenseAqualityDmaintenanceEnables querying FDA drug label information including adverse reactions, warnings, and indications via natural language.56 npm1GPL 3.0
- AlicenseAqualityDmaintenanceProvides LLM-optimized access to FDA data through the OpenFDA API and direct regulatory decision document retrieval, covering all 21 OpenFDA endpoints plus 510(k) summaries, De Novo decisions, and PMA approvals.41MIT
- AlicenseNot gradedqualityDmaintenanceProvides real-time access to medical data including drug interactions, ICD-10 codes, FDA adverse event reports, and clinical guidelines. It enables LLMs to query databases like openFDA, PubMed, and CMS for pharmaceutical and clinical information.1MIT
TDQS
Scored across 2 tools
The two tools target distinct OpenFDA endpoints: drug labels and adverse events. There is no overlap in their purposes, making it clear which to use.
Both names follow a verb_noun pattern, but one uses 'search' and the other uses 'get', which is a minor inconsistency. Otherwise the pattern is clear and predictable.
With only two tools, the server feels thin for the OpenFDA domain, which has many potential endpoints. However, the two tools cover two common use cases, so the count is borderline acceptable.
OpenFDA offers many data types (e.g., recalls, enforcement reports, labeling for drugs and devices). Only drug labels and adverse events are covered, leaving significant gaps that would force agents to look elsewhere.